Peptide therapy to help the heart relax in diastolic (HFpEF) heart failure
C-terminal Peptide of Cardiac Troponin I for the Treatment of Diastolic Hear Failure
This project uses a small piece of a heart protein to help people with diastolic heart failure (HFpEF) have better heart relaxation.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Illinois at Chicago NIH-funded |
| Lab location | 1 site (Chicago, UNITED STATES) |
| Project ID | NIH-11330277 on NIH RePORTER |
What this research studies
Researchers are working on a peptide taken from the tail end of a heart protein (cardiac troponin I) called cTnI-C27 to see if it helps the heart relax more effectively. In the lab they will study how the peptide binds to the heart's contraction machinery and changes calcium sensitivity, using biochemical and genetic tests. They will also use mouse models of diastolic dysfunction to look for improved heart relaxation and function. The long-term aim is to move toward a targeted treatment for people with HFpEF, a type of heart failure that currently has few effective therapies.
Who could benefit from this research
Good fit: Adults with diastolic heart failure (HFpEF) and signs of impaired relaxation would be the most likely candidates for future trials of this therapy.
Not a fit: People whose main problem is reduced ejection fraction (HFrEF) or breathlessness from non-cardiac causes are unlikely to benefit from this peptide approach.
Why it matters
Potential benefit: If successful, this could become a new targeted treatment that improves heart relaxation and symptoms in people with HFpEF.
How similar studies have performed: Related myofilament-targeting strategies have shown encouraging results in laboratory and animal studies, but there are no established human treatments yet using this exact approach.
Where this research is happening
Chicago, UNITED STATES
- University of Illinois at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Jin, Jian-Ping — University of Illinois at Chicago
- Study coordinator: Jin, Jian-Ping
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.